Business Wire

As Europe Prepares for Ambitious Revisions to His Regulatory Framework to Support the Green Deal’s Targets, Key Findings From the Largest European Hydrogen Mobility Initiative Highlight the Role Hydrogen Can Play

14.1.2021 13:03:00 EET | Business Wire | Press release

Share

A flagship project for hydrogen mobility involving nearly 50 organisations at the forefront of the sector has today published its final report detailing the key findings and learnings. The findings are released at a crucial time as the European Green Deal seeks a 90% reduction in transport related emissions by 2050.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005025/en/

Hydrogen Mobility Europe (H2ME) has completed its first phase and compiled a rich dataset since initiating in 2016: 630 hydrogen fuel cell electric vehicles have been deployed in 10 countries and 37 new hydrogen refuelling stations installed in 8 countries, achieving 14.5 million km driven and 147 tonnes of hydrogen dispensed across 68,000 refuelling events. It is the largest European deployment for hydrogen mobility to date and demonstrates the commercial potential to rollout fuel cell electric vehicles (FCEVs) and hydrogen refuelling stations (HRS) for large and small fleets.

Following the conclusion of its initial phase, H2ME recommends national and international incentives that ensure the dispensed cost of low carbon hydrogen is competitive for vehicle operators to create a level playing field with other zero emission vehicles. National, regional, and local policies that ensure continued development of the industry are also recommended. The expansion of hydrogen infrastructure as a result of H2ME, co-funded by the FCH-JU, means more FCEVs now have access to refuelling stations however the limited infrastructure prevents full operational advantages of FCEVs being realised.

Incentives such as purchase grants and tax exemptions will unlock demand from vehicle operators and bring market confidence to vehicle suppliers. Similarly, financial support applied per unit (kg) of hydrogen sold, similar to the feed in tariffs which were applied to stimulate early renewable energy uptake, will lower the price of green hydrogen at the pump. This will enable high utilisation of refuelling stations, which strengthens its business case, demonstrated by clusters of captive fleets with high mileage and heavy-duty cycles as they have significantly lower costs per kilogram of hydrogen.

The second phase of deployment will focus on developing state of the art refuelling stations, increased options for producing green hydrogen, and targeting a wider range of vehicles (from light duty to heavy duty vehicles). The lessons from phase one show that future hydrogen mobility strategies should focus more on high mileage and heavy-duty applications to provide the anchor demand for new installations. This will provide a stronger business case to the HRS operators.

Hydrogen could play a key role in enabling high mileage applications can transition to zero emission as these applications have specific operational needs such as long range and short refuelling time, that can be met by FCEVs. The overall cost of operating FCEVs in these fleets is expected to decrease rapidly in the coming years. For example, an analysis from the ZEFER project found that for high mileages applications such as taxis, and with hydrogen at €7,5/kg, FCEVs can reach parity on a total cost of ownership basis with petrol/diesel hybrids in the next 5 years.

In Denmark three Hyundai ix35 FCEVs are used by the Municipality of Copenhagen for a variety of duties as part of H2ME. They average 120 km travelled per day, with recorded distances up to 500 km in a single day, and have access to three refuelling stations within driving range. Well-to-wheel (WTW) emissions from FCEVs in Denmark are calculated at 20 gCO2e/km, compared to 34 gCO2e/km for a battery electric vehicle, 47 gCO2e/km for a battery electric SUV and 217 gCO2e/km for a diesel comparator. The use of 100% green certified electrolytic hydrogen is key to the low emissions, however FCEVs still achieve significantly lower WTW emissions than diesel or gasoline vehicles even if using hydrogen derived from fossil fuels. Similar analysis conducted in Germany and France found that FCEVs achieve significant emission savings compared to diesel or gasoline vehicles, even if using fossil-derived hydrogen, and can be even more significantly when using low carbon or green hydrogen.

The fuel cell electric vehicles deployed have completed up to 600 km of driving range on a single tank, and prove reliable with over 99% availability over their operational usage since 2016. The confirmation of technology readiness, emerging business cases and customer proposition in the project shows a path towards commercialisation.

With increasing needs for zero emissions mobility solutions to achieve environmental targets, and economics expecting to improve rapidly at scale, there is a strong case to support the commercial rollout for hydrogen mobility.

Bart Biebuyck, Executive Director at Fuel Cells and Hydrogen Joint Undertaking (FCH JU), said: “The first phase of H2ME has demonstrated that light duty hydrogen fuel cell vehicles are performant and nearing market competition with other zero emissions vehicles for high mileage applications, like taxi fleets. In addition, our flagship project was successful in supporting the onset of a European H2 infrastructure for road transport. Today, Europe has a card to play: By integrating these learnings into the heavy duty truck sector, it can capitalise on best practices of vehicles fleets and infrastructure management, making an essential contribution to a green post-Covid recovery of our economy”.

Ben Madden, Director at Element Energy, said: “We are pleased to share the results and findings of the H2ME 1 project. This project would not have been possible without the support from the FCH JU and commitment of all partners involved. Grants to support early stage commercial deployments are a critical step in the path towards commercialisation and will remain one of the key financial tools at the European level in the coming year to develop solutions for zero-emission mobility. Element Energy is very proud to have coordinated this project and to continue supporting the largest hydrogen mobility initiative in Europe.”

Dr Duncan Yellen, Managing Director at ITM Motive, said: “Participation in the H2ME project has been invaluable in providing insights into both the engineering and customer requirements for our future build programme. Thanks to the learning provided here and through other funded projects we are confident in our ability to provide the best possible designs for building the next generation of Hydrogen Refuelling Stations across the UK to match the needs of heavy duty vehicles, high use car fleets and rail.”

Nikolas Iwan, CEO of H2 Mobility, said: “20 of the more than 90 stations in Germany have been built in the H2ME project. We are proud to be partner in the largest European hydrogen mobility initiative. Collaboration is the key to a successful mobility transition, especially in the next phase were rules and regulations have to be set for the light and heavy duty transport sector.”

Anna Margrét Kornelíusdóttir, Project Manager at Icelandic New Energy Ltd, said: "The Nordic countries have long had a faith in clean hydrogen produced from their abundant renewable energy resources. Our governments have made this clear by implementing generous economic incentives and ambitious strategies.

“H2ME has demonstrated the use and reliability of hydrogen and fuel cell technology for passenger vehicles across Europe and proven the feasibility of hydrogen as a transport fuel.

“Amid rising pressure to reach decarbonisation goals, hydrogen technology represents a low carbon and low emission energy solution that can play a vital role in the next steps addressing a transition to clean energy, not only for passenger vehicles, but also heavy-duty trucks, marine vessels and even aviation”.

- Ends -

Notes to Editor

Download the full report here: https://h2me.eu/wp-content/uploads/2021/01/H2ME_Emerging-Conclusions2020.pdf

Image: https://we.tl/t-rvTibkH4Bz

Caption: 37 new hydrogen refuelling stations have been installed in 8 countries as part of the H2ME project

About H2ME

This €170 million demonstration project is co-funded with €67 million from the Fuel Cells and Hydrogen Joint Undertaking (FCH JU), a public-private partnership supporting fuel cell and hydrogen energy technologies in Europe.

Partners include project lead Element Energy, alongside AGA, Air Liquide, AREVA H2GEN, Audi, BOC, BMW, Cenex, City of Copenhagen (Kobenhavns Kommune), Communauté d’Agglomération Sarreguemines Confluence, CNR, Daimler AG, Danish Hydrogen Fuel, EIFER, GNVERT, H2 Mobility Deutschland, Honda, Hydrogen Denmark (Brintbranchen), Hydrogene de France, hySOLUTIONS, Hyundai, Icelandic New Energy Ltd, Intelligent Energy, Islenska Vetnisfelagid (H2 Iceland), Kerkhof, ITM Power, Linde AG, McPhy Energy, Michelin, Nel Hydrogen, Netherlands Ministry of Infrastructure and Water Management (Ministerie Van Infrastructuur en Waterstaat), Nissan, OMV, OPEN ENERGI, Renault, Renault Trucks, SEMITAN, Stedin, STEP, Symbio, Toyota, The University of Manchester, WaterstofNet.

This project has received funding from the Fuel Cells and Hydrogen 2 Joint Undertaking under grant agreement No 671438 & No 700350. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, Hydrogen Europe and Hydrogen Europe research.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Declan Shepherd | PR and Social Media Officer at Cenex
Email: Declan.Shepherd@Cenex.co.uk
Website: www.h2me.eu
Twitter: @H2ME_EU

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye